.png)
Agenzia Italiana del Farmaco
home
Highlights
-
09 Feb 2026
Press releases
Memorandum of Understanding between AIFA and NADO (National Anti-Doping Organisation)
The Italian Medicines Agency provides NADO with information on doping medicines authorised in Italy, extracted from its database, for the creation of a platform dedicated to athletes.
-
03 Feb 2026
Press releases
Proton Pump Inhibitors (PPIs): AIFA introduces Note ‘N01’
A new Note will regulate the conditions for prescribing Proton Pump Inhibitors (PPIs) covered by the National Health Service.
-
29 Jan 2026
Press releases
AIFA monitoring of pharmaceutical expenditure January-September 2025
Expenditure on medicines dispensed through pharmacies open to the public amounted to €6,425 million (6.33% of the FSN), while expenditure on medicines purchased directly by public healthcare facilities amounted to €11,811 million (11.64% of the FSN).
-
28 Jan 2026
Press releases
Cystic fibrosis: the number of patients eligible for free access to new CFTR modulator medicines has been expanded
The Board of Directors' approval covered two orphan drugs, two new molecules, seven generics, three biosimilars and five therapeutic indication extensions.
News
18 Feb 2026
Monitoring pharmaceutical expenditure
Biosimilar medicines in Italy: AIFA reports updated
17 Feb 2026
Access to medicinal products
Textile Supplementary Series for patch tests
16 Feb 2026
Transparency Lists
AIFA updates the Transparency Lists
13 Feb 2026
Safety of medicinal products
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9-12 February 2026
11 Feb 2026
Companies Section
New Multi-Beneficiary Mode for Online Payments
06 Feb 2026
Quality and Inspections
Direct communication with healthcare professionals on Arixtra (fondaparinux sodium)
FarmaciLine
Questions regarding drug efficacy, safety and availability
TOLL-FREE NUMBER
Services
Interactive OsMed - The use of medicines in Italy
An interactive consultation of data on the use of medicines in Italy in the general and regional population, described in terms of expenditure, volumes, typology
Media
